April 9 - Hoffmann-La Roche Canada announced today that Health Canada has approved AVASTIN (bevacizumab), in combination with paclitaxel-carboplatin chemotherapy regimen, for treatment of patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC), the most common form of this devastating disease.
The details can be read here.
No comments:
Post a Comment